| 000 | 01770 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514184916.0 | ||
| 264 | 0 | _c20040527 | |
| 008 | 200405s 0 0 eng d | ||
| 022 | _a1478-3223 | ||
| 024 | 7 |
_a10.1111/j.1478-3231.2004.00893.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, Chih-Lin | |
| 245 | 0 | 0 |
_aEvolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. _h[electronic resource] |
| 260 |
_bLiver international : official journal of the International Association for the Study of the Liver _cFeb 2004 |
||
| 300 |
_a9-15 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xpharmacology |
| 650 | 0 | 4 |
_aDNA-Directed DNA Polymerase _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis B Core Antigens _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xgenetics |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLamivudine _xpharmacology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMutation _xdrug effects |
| 650 | 0 | 4 |
_aPromoter Regions, Genetic _xdrug effects |
| 650 | 0 | 4 |
_aVirus Replication _xdrug effects |
| 700 | 1 | _aLiao, Li-Ying | |
| 700 | 1 | _aWang, Chaur-Shine | |
| 700 | 1 | _aChen, Pei-Jer | |
| 700 | 1 | _aLai, Ming-Yang | |
| 700 | 1 | _aChen, Ding-Shinn | |
| 700 | 1 | _aKao, Jia-Horng | |
| 773 | 0 |
_tLiver international : official journal of the International Association for the Study of the Liver _gvol. 24 _gno. 1 _gp. 9-15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1478-3231.2004.00893.x _zAvailable from publisher's website |
| 999 |
_c14813512 _d14813512 |
||